ТРАНСКРИПТОМНЫЙ АНАЛИЗ КЛЕТОК МЕЛАНОМЫ, ПОЛУЧЕННЫХ ИЗ РАЗЛИЧНЫХ УЧАСТКОВ ПЕРВИЧНОЙ ОПУХОЛИ by M. Aksenenko B. et al.
DOI: 10.21294/1814-4861-2018-17-4-59-66
УДК: 6-006.81-091.8:577.21
Для цитирования: Аксененко М.Б., Комина А.В., Палкина Н.В., Аверчук А.С., Рыбников Ю.А., Дыхно Ю.А., 
Рукша Т.Г. Транскриптомный анализ клеток меланомы, полученных из различных участков первичной опухоли. Сибирский 
онкологический журнал. 2018; 17 (4): 59–66. – doi: 10.21294/1814-4861-2018-17-4-59-66.
For citation: Aksenenko M.B., Komina A.V., Palkina N.V., Averchuk A.S., Rybnikov Yu.A., Dyhno Yu.A., Ruksha T.G. 
transcriptomic analysis of melanoma cells extracted from different sites of the primary tumor. Siberian Journal of Oncology. 2018; 
17 (4): 59–66. – doi: 10.21294/1814-4861-2018-17-4-59-66.
трансКриптомный анализ КлетоК меланомы, 
полученныХ из различныХ участКоВ перВичной 
опуХоли
м.Б. аксененко1, а.В. Комина1, н.В. палкина1, а.с. аверчук1, 
Ю.а. рыбников2, Ю.а. дыхно1, т.г. рукша1
ФГБОУ ВО «Красноярский государственный медицинский университет 
имени проф. В.Ф. Войно-ясенецкого» Министерства здравоохранения Российской Федерации, 
г. Красноярск, Россия1
Россия, 660022, г. Красноярск, ул. П. Железняка, 1. E-mail: tatyana_ruksha@mail.ru1
КГБУЗ «Красноярский краевой клинический онкологический диспансер имени А.И. Крыжановского», 
г. Красноярск, Россия2
Россия, 660133, г. Красноярск, ул. 1-ая Смоленская, 162
аннотация
Введение. Внутриопухолевая гетерогенность представляет собой характерную черту большинства 
злокачественных новообразований, в том числе и меланомы кожи. данное свойство является одним 
из препятствий для проведения эффективной таргетной терапии, поскольку у различных субклонов 
опухолевых клеток наблюдается вариабельная чувствительность к данным препаратам. С современ-
ных позиций терапия злокачественных новообразований требует персонифицированного подхода для 
каждого конкретного пациента. цель исследования – оценка возможных различий между тканями 
меланомы, выделенными из различных участков первичной опухоли одного пациента на транскрип-
томном уровне. материал и методы. В работе были использованы культуры клеток меланомы, полу-
ченные из центральной и периферической частей первичной опухоли двух пациентов. Исследование 
транскриптомов клеток проводили методом микрочипирования с последующим биоинформатическим 
анализом. результаты. В клетках меланомы первого пациента, полученных из центрального и пери-
ферического участков одной опухоли, не было выявлено различий по транскриптомному профилю. У 
второго пациента имели место существенные различия (по 2953 транскриптам из 48226). В клетках, 
полученных из центрального участка опухоли, выявлено повышение мРНК генов, кодирующих белки, 
ассоциированные с иммунным ответом опухоли, транспортные белки ABC-семейства, сигнальные 
молекулы класса цитокинов. В культуре клеток, выделенной из периферического участка этой же опу-
холи, зарегистрировано увеличение уровня мРНК генов, кодирующих белки внеклеточного матрикса 
и воспалительного ответа. В целом различия между субклонами клеток второго пациента касались 
ряда сигнальных каскадов, играющих ведущую роль в онкогенезе (MApK, pI3K-Akt-mToR, VEGFA-
VEGFR2 и др). заключение. Проведенное исследование позволяет оценить возможные различия 
между клетками внутри опухоли на транскрипционном уровне с целью поиска новых подходов для 
персонифицированной терапии.
Ключевые слова: меланома, гетерогенность, транскриптом, микроокружение.
TRANSCRIPTOMIC ANALYSIS OF MELANOMA CELLS 
EXTRACTED FROM DIFFERENT SITES OF THE PRIMARY TuMOR
M.b. Aksenenko1, A.V. Komina1, N.V. Palkina1, A.S. Averchuk1, 
Yu.A. Rybnikov2, Yu.A. Dyhno1, T.G. Ruksha1
59СИБИРСКИЙ ОНКОЛОГИЧЕСКИЙ ЖУРНАЛ. 2018; 17(4): 59–66
   рукша татьяна геннадьевна, tatyana_ruksha@mail.ru
60 SIBERIAN JoURNAL oF oNCoLoGY. 2018; 17(4): 59–66
CLINICAL STuDIES
professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
of the Ministry of Health Care of the Russian Federation, Krasnoyarsk, Russia1
1, p. Zheleznyaka Street, 660022-Krasnoyarsk, Russia. E-mail: tatyana_ruksha@mail.ru1
A.I. Kryzhanovsky Krasnoyarsk Region Clinical oncology Center, Krasnoyarsk, Russia2
16, 1st Smolenskaya Street, 660133-Krasnoyarsk, Russia2
Abstract
Introduction. Intratumor heterogeneity is a characteristic feature for most malignant tumors, including 
cutaneous melanoma. This property represents one of the main obstacles for effective targeted therapy, 
due to the different sensitivity to chemotherapeutic agents on various tumor cells subclones. Treatment of 
malignant tumors requires an individual approach to choose the most appropriate treatment regimen. The 
purpose of the study was to evaluate differences in melanoma tissue samples obtained from different parts 
of one patient’s primary tumor at the transcriptomic level. Material and Methods. Melanoma cell cultures 
obtained from both central and peripheral parts of the primary tumor of two patients were used in the study. 
Results. Subclones from different parts of the first patient’s tumor were similar, whereas the second patient 
demonstrated significant differences at the transcriptomic level (in 2953 transcripts out of 48226). In the 
cells of the central zone of the second patient’s tumor, an increase in mRNA of the genes encoding proteins 
associated with tumor-specific immune response, as well as ABC-family transport proteins and cytokine 
signaling molecules, were noted. In the cells from the peripheral area of the same tumor, a more intensive 
transcription of genes encoding extracellular matrix and inflammatory response proteins was observed. Taken 
all round, the differences between the subclones of the second patient’s cells were relevant to some signaling 
cascades playing a leading role in oncogenesis (MApK, pI3K-Akt-mToR, VEGFA-VEGFR2, etc.). Conclusion. 
The study allowed evaluation of differences between cancer cells within a tumor at the transcriptional level 
in order to search for further approaches to personalized melanoma therapy.
Keywords: melanoma, heterogeneity, transcriptome, microenvironment.
Introduction
Intratumor heterogeneity is a serious problem 
in terms of cancer treatment. With the development 
of a tumor cell genome, genetically heterogeneous 
subclones with different biological characteristics 
and variable sensitivity to chemotherapy appear in 
the primary tumor [1]. The development of malignant 
tumor and its growth is an active evolutionary 
process that results in a tumor consisting of cells 
with heterogeneous molecular characteristics [2]. 
This diversity entails the development of resistance 
to treatment in cancer patients [3].
The diverse molecular portrait of the cells that form 
one tumor can be a result of a set of changes at the 
genetic and epigenetic levels [4]. Among such changes, 
special attention should be given to differences in 
transcriptome profile of the cell. This is due to the fact 
that the transcription is a dynamic process that projects 
functional cell characteristics and predetermines 
different aspects of cells’ biological activity, forming 
an individual molecular landscape of the development 
of cancer cells’ subclones [5].
The aim of this research is a comparative analysis 
of transcriptomic profiles of melanoma cells derived 
from different parts of one patient’s primary tumor.
Material and Methods
In the present study we used surgical specimens 
of two patients treated at the General Oncosurgery 
Department of A.I. Kryzhanovsky Krasnoyarsk Region 
Clinical Oncology Center, Krasnoyarsk, Russia.
The study was approved by the ethical Committee 
of Professor V.F. Voino-Yasenetsky Krasnoyarsk 
State Medical University (record No. 73/2016 
dated 16.12.2016) and the ethical Committee of 
A.I. Kryzhanovsky Krasnoyarsk Region Clinical 
Oncology Center (record No. 8 dated 14.062.2017). 
Patients’ clinical characteristics are shown in Table 1.
Immediately after surgical excision, a tumor 
fragment of at least 8 mm3 and weighing at least 
300 mg was immersed in a tube containing a culture 
medium RPMI-1640 (Gibco, Life Technologies, 
Paisley, UK) with the addition of 20% fetal bovine 
serum (Gibco, Life Technologies, Paisley, UK) and 
antibiotic-antimicotic complex: 100 U/ml penicillin 
G, 100 µg/ml streptomycin, 0.025 µg/ml amphotericin 
B (HyClone laboratories, USA) and was transported 
in ice. Two pieces were then aseptically separated 
from the tumor tissue: one from the central part of 
the tumor and one from the peripheral part of the 
tumor. If necessary, the obtained fragments were 
mechanically cleaned of necrotic tissue, washed in a 
sterile balanced Hanks salt solution (HBSS) (Gibco®, 
Life Technologies, Paisley, UK) and crushed by 
crossed scalpels.
The obtained tumor fragments were disaggregated 
by incubation in 0.25% trypsin solution with EDTA 
(Gibco, Life Technologies, Paisley, UK) in an amount 
of 1 ml of trypsin for every 100 mg of tissue at +37°C 
for 15-20 minutes. At the end of incubation, the 
suspension was centrifuged on a centrifuge CLMN-
P10-01-Elecon (“Liston”, Zhukov, Russia) at a speed 
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of 1000 rpm for 5 minutes. The obtained cellular 
precipitate was resuspended in 5 ml of RPMI-1640 
nutrient medium with L-glutamine (Gibco®, Life 
Technologies, Paisley, UK), 10% fetal bovine serum 
(Gibco®, Life Technologies, Paisley, UK) and a 
mixture of antibiotic-antimicotic complex (HyClone 
laboratories, USA) and placed in a culture tube, in 
which further cultivation was carried out in CO
2
-
incubator (Sanyo, Osaka, Japan) with 5% of carbon 
dioxide, at +37°C. The first change of the nutrient 
medium was carried out 48 hours after the beginning 
of cultivation after the visual cells’ adhesion to the 
adhesive surface of the tube. The first cell passage was 
carried out 4 days later and subsequent cell passages 
were carried out every 3 days of incubation.
To study the transcriptome of melanoma cells 
isolated from the central and peripheral parts of the 
tumor, the cells were transplanted into a 24-well plate at 
a concentration of 2×105 cells/ml. The culture medium 
was changed 24 hours after the cells’ adhesion to the 
adhesive surface, with a subsequent culturing during 
72 hours. At the end cells were removed using 0.25% 
trypsin with EDTA, washed in 0.01M phosphate-
buffered saline and then the total RNA was isolated. 
RecoverAll™ Total Nucleic Acid Isolation kit (Ambion, 
Lithuania) was used for isolation according to the 
manufacturer’s protocol. The concentration of purified 
total RNA was determined by Qubit® 2.0 fluorimeter 
(Singapore) using Qubit™ RNA HS Assay Kit (Ref. 
Q32852, Invitrogen™, Eugene, Oregon, USA).
The transcriptome of melanoma cells isolated 
from different parts of the tumor was studied using 
the GeneAtlas® system (Affymetrix, USA). For 
this purpose, 10 ng of purified total RNA were 
pretreated with the sample preparation kit titled 
GeneChip™ WT Pico Kit (Applied Biosystems™, 
Santa Clara, California, USA) in accordance with 
the manufacturer’s protocol. Then, molecules were 
hybridized to GeneChip™ Human Gene 2.1 ST Array 
Strip microchips (Applied Biosystems™, Santa Clara, 
California, USA) with the reagents from GeneAtlas 
Hybridization, Wash, and Stain Kit for WT Array 
Strips (Applied Biosystems™, Santa Clara, California, 
USA). After 20 hours of hybridization microchips 
were washed and stained with solutions for washing 
and staining from the same set in the Fluidic station 
of the GeneAtlas® system. The detection of the 
microarray results was made in the Imaging station 
of this system.
Quality control (QC) of microarray was performed 
by the software system automatically due to the 
introduction of control RNA molecules into the study 
at the stages of sample preparation and hybridization. 
The fluorescence data analysis with its transformation 
into relative mRNA expression levels was carried out 
using the Expression Console (“Affymetrix”, USA). 
Transcriptome Analysis Console 3.0 (“Affymetrix”, 
USA) was used for statistical processing of microarray 
data. The non-parametric t-test ANOVA was used 
for data comparing. The statistical significance in 
transcriptomic profile differences was evaluated 
after an adjustment to the false discovery rate (FDR) 
criterion proposed by Benjamin, Hochberg for multiple 
comparisons [6]. The differences were statistically 
significant at pFDR <0.05.
To assess the biological significance of individual 
genes, the GO (Gene ontology) project databases 
were used (https://www.ebi.ac.uk/QuickGO/, last 
access 06.11.2017), the analysis of genes’ ontology 
of differentially expressed genes was carried out 
using Panther 13.1 database. Analysis of the clusters’ 
biological role based on the microarray results was 
performed in the database DAVID 6.8 (https://david.
ncifcrf.gov/home.jsp, last access 10.11.2017).
Results
The analysis of transcriptomic profiles of melanoma 
cells obtained from different parts of the first patient’s 
tumor (Krsgmu-HS-Mel-CD-T-230317-Centr and 
Krsgmu-HS-Mel-CD-T-230317-K) revealed no 
differences between them. However, different results 
were shown in melanoma cells of the second patient – 
Krsgmu-HS-Mel-RI-T-040417-Centr and Krsgmu-
HS-Mel-RI-T-040417-K. Profiles of these cultures 
Figure 1. Hierarchical clustering of genes with different levels 
of transcription in melanoma cells isolated from the central 
part (Krsgmu-HS-Mel-RI-T-040417-Centr) and peripheral part 
(Krsgmu-HS-Mel-RI-T-040417-K) of the same tumor
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differed in the level of 2953 transcripts. Out of them, 
the level of 1735 transcripts was two or more times 
higher, while the level of 1218 transcripts was two or 
more times lower in the cells of the central part of the 
tumor compared to the cells of the peripheral part of 
the tumor (Figure 1).
The transcript levels of genes encoding 42 proteins 
were more than 25 times higher, whereas transcripts 
of genes encoding 43 proteins were more than 25 
times lower in cells from the central tumor part than in 
cells from the peripheral part. Proteins with increased 
mRNA levels in cells obtained from the central 
tumor parts belonged to the proteins responsible for 
various intracellular processes, including intercellular 
adhesion, transport of ions and metabolites. The most 
significant changes were detected in mRNA levels 
encoding proteins ABCC2, SNAP25, CCL2, OAS1, 
MAGEA3, MAGEB2, MAGEA6, DNER, TPTE, 
HLA-DRB5, DNER. Proteins, in which the mRNA 
levels were 25 times lower in cells from the central 
tumor part than in cells from the peripheral tumor part, 
included intercellular adhesion molecules, extracellular 
matrix proteins, growth factors, signal transduction 
proteins, apoptotic proteins (NEXN, PPP1R14A, 
POSTN, chipboard, B3GALT2, SEMA7A, FGF7, 
RIMS1, FBLN5, SCUBE3, PCDH18, COL1A2, 
TNFRSF10D, ADAMTS5, BGN).
Among the transcripts of genes that have a moderate 
increase in the level of cells obtained from the central 
part of the tumor compared with the periphery of the 
tumor (more than 5 times but less than 25 times), 423 
transcripts were identified, with a 5-25 fold decrease 
in the level of 275 transcripts.
Proteins, which had increased mRNA levels in 
cells from the central part of the tumor compared 
to its periphery, were represented by the proteins of 
the Wnt-signaling cascade, proteins for intercellular 
contacts and adhesion, cadherins, regulators of the p53 
signaling pathway, molecules of the EGF signaling 
pathways, and various cytokines. A similar trend was 
observed for the proteins with mRNA levels, which 
were lower in the culture of cells obtained from the 
central tumor sites compared to its periphery. The most 
common were the transcripts of genes of intercellular 
adhesion molecules, cadherin: CDH8, PCDHB3, 
PCDHB2, EN1, TGFBR1, ACTA2, TCF7L2, EDN1, 
PLCB4, SFRP4, and genes encoding proteins 
involved in angiogenesis: PRKD1, CRYAB, TCF7L2, 
PDGFRB, tissue factor F3.
Compared to the peripheral part of the tumor, 
genes’ transcripts with a moderate decrease (a 5-25-
fold) in mRNA levels in the central part represented the 
largest group since it contained 1249 altered transcripts 
of isolated genes, and 896 transcripts had a 2-5-fold 
decrease in mRNA levels. Among the altered gene 
transcripts, there were mRNAs of proteins involved 
in angiogenesis (the corresponding proteins are 
components of the integrin and endothelin signaling 
pathways.
There were identified 950 genes’ transcripts with 
slightly elevated levels (more than 2 times, but less 
than 5 times) in cells obtained from the central tumor 
part compared to its periphery, and a 2-5-fold decrease 
was observed in the levels of 750 genes’ transcripts. 
Proteins, the mRNA levels of which were elevated in 
the cells from the central parts of the tumor compared 
to its periphery, were represented by proteins-
participants of the inflammatory response: PIK3CB, 
PLA2G4A, CXCL8, COL14A1, IL1B, NFATC2, 
PRKX, PLCG2, CCL5, RELB, RGS17, NFKBIA, 
ARRB1, GNA1, PDK1, as well as T-lymphocytes’ 
activators: HLA-DQA1, MAP3K1, NFATC2, LCP2. 
Proteins of intercellular adhesion, cadherins and 
integrins dominated among proteins with a 2-5-fold 
decrease in the mRNA levels.
The results obtained showed that the altered genes’ 
transcripts were the components of 642 signaling 
pathways. Among these signaling cascades, we 
identified signaling pathways, which included 10 
or more proteins, the mRNA expression level of 
which was changed according to our findings. The 
transcriptomic profile revealed that mRNAs of genes 
with the increased transcription level in cells obtained 
from the central part of the tumor compared to cells 
obtained from the peripheral part of the tumor were 
involved into 40 signaling cascades, and mRNAs of 
genes with the decreased transcription level were 
involved only into 19 signaling pathways (Table 2).
Discussion
Transcriptomic profiling data analysis showed an 
increase in mRNAs of proteins, such as: melanoma-
associated antigen-3 and melanoma-associated 
antigen B2. A 93.81-fold increase in the mRNA 
level of these proteins was observed in the center 
of the tumor. According to the literature review 
results, these genes are considered to be target genes 
recognized by cytotoxic T-cells under antigen-specific 
immunotherapy in skin melanoma patients [7].
Differences in the transcriptomic profile were 
revealed in ABC transporter proteins family. These 
proteins are considered to be associated with the 
formation of a multiple drug resistance. The ABCC2 
protein mRNA level was 29.9 times higher in the 
center of the tumor. It is known that an increase in the 
expression activity of this protein on the tumor cells 
membrane can result in more intensive elimination of 
therapeutic agents from the cell, causing a decrease in 
the intracellular drug concentration, which is necessary 
for the efficient tumor growth inhibition [8]. This 
fact can explain why different tumor subclones yield 
a different therapeutic response to the anti-tumor 
agent.
A 98.14-fold increase in CCL2 chemokine mRNA 
expression in the center of the tumor indicates that 
there are different types of immunological reactions 
in central and peripheral parts of the tumor. This 
protein is known to be actively expressed by tumor-
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тable 1
Characteristics of the studied samples
No Patients’ clinical data 
Code number of the cell cultures, obtained 
from the tumor fragment
Tumor fragment localization
1
Patient K., a 30-year-old female, super-
ficial spreading melanoma of the right 
lower leg
Krsgmu-HS-Mel-СD-T-230317-Centr Center
Krsgmu-HS-Mel-СD-T-230317-K Peripheral part
2
Patient B., a 64-year-old male, su-
perficial spreading melanoma of the 
interscapular area
Krsgmu-HS-Mel-RI-T-040417-Centr Center
Krsgmu-HS-Mel-RI-T-040417-К Peripheral part
Table 2
Signaling pathways, involved in the regulation of differentially altered genes, according to the 
transcriptome analysis in the cell culture, obtained from different parts of the tumor
Signaling pathway *
Number of transcripts 
increased in the central 
tumor part compared to 
the peripheral one
Signaling pathway *
Number of transcripts 
decreased in the central 
tumor part compared to 
the peripheral one
Nuclear Receptors Meta-Pathway 33 miR-targeted genes in lymphocytes 37
miR-targeted genes in lymphocytes 27 miR-targeted genes in muscle cell 36
Retinoblastoma (RB) in Cancer 26 Focal Adhesion-PI3K-Akt-mTOR-
signaling pathway
27
Cell Cycle 19 Focal Adhesion 21
Circadian rythm related genes 19 Mesodermal Commitment Pathway 20
PI3K-Akt Signaling Pathway 17 MAPK Signaling Pathway 19
MAPK Signaling Pathway 17 Wnt Signaling Pathway 14
Ectoderm Differentiation 17 ESC Pluripotency Pathways 14
Endoderm Differentiation 17 Vitamin D Receptor Pathway 13
Mesodermal Commitment Pathway 15 Regulation of Actin Cytoskeleton 13
VEGFA-VEGFR2 Signaling 
Pathway
15 miR-targeted genes in leukocytes 10
Chemokine Signaling Pathway 15 EGFR1 Signaling Pathway 10
* This table shows a total of 15 signaling pathways for both increased and decreased transcripts with the largest number of mRNAs involved into the 
signaling cascade.
associated macrophages, as well as by tumor cells 
themselves. In addition, the biological effect of this 
protein correlates with its concentration in the tumor 
tissue: at high concentrations of CCL2, a stimulation 
of classically activated M1 macrophages takes place, 
and a cytostatic effect in tumor cells occurs, whereas 
at low concentrations of CCL2, an accumulation of 
already alternatively activated M2 macrophages in the 
tissue takes place, which produces an inverse effect 
and induces an enhanced proliferation activity of the 
tumor cells [9].
The proteins whose mRNA levels were more than 
25 times lower in the center than in the peripheral 
part of the tumor were mainly proteins-components of 
extracellular matrix. This fact can be due to a higher 
level of stromal components in the peripheral part 
of the tumor than in its central part. The change of 
the expression profile corresponds to data obtained 
from colorectal cancer research that reported the 
predominance of proteins forming components of 
extracellular matrix: collagens, tissue inhibitors of 
matrix metalloproteins (COL6A3, COL1A2, POSTN, 
TIMP2 and others) at the peripheral part of the tumor 
[10].
Among both increased and decreased gene 
transcripts in the central part of the tumor in 
comparison with its periphery, there were mRNAs, 
coding proteins that were components of the Wnt 
signaling pathway. The components of the Wnt 
signaling pathway are known to take part at all stages 
of skin melanoma development. For example, the 
transcription of a well-known c-myc oncogene whose 
enhanced expression is characteristic for various 
neoplasms, including melanoma of the skin, is induced 
by means of the β-catenin signaling cascade [11], the 
gene expression of negative regulators of a canonical 
Wnt signaling pathway being often suppressed. For 
example, the production of Dkk-1, 2 and 3 that inhibit 
the β-catenin signaling cascade by means of binding 
with co-receptor LRP5/6 is significantly reduced or 
absent in melanoma cells [12].
The transcriptome profile revealed that, mRNAs 
of genes with the elevated transcription level in cells 
obtained from the tumor center were involved in 40 
signaling cascades, whereas mRNAs of genes with 
decreased transcription level were involved in only 19 
signaling pathways. According to the bioinformatics 
analysis data, mRNA profile changes in melanoma 
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cells obtained from both the central and peripheral 
parts of the tumor affected genes-components of 
signaling pathways traditionally associated with 
cancerogenesis (MAPK, PI3K-Akt-mTOR, VEGFA-
VEGFR2, Focal adhesion, Wnt signaling pathway). 
Proteins of the MAPK signaling cascade are one of the 
key targets in skin melanoma therapy although many 
patients suffering from metastatic melanoma showed 
acquired resistance to MAPK inhibitors.
One of the major mechanisms of MAPK-inhibitor 
resistance formation is the realization of the intratumor 
heterogeneity phenomenon. High plasticity of 
melanoma cells provokes both a clonal evolution of 
genetic resistance (for example due to a mutation in 
genes that code components of the MAPK or PI3K/
AKT/PTEN signaling cascades) and an appearance of 
cel phenotypes that are functionally and metabolically 
resistant to various therapeutic agents [13]. Thus, 
melanoma cells, like ‘a moving target’, drift among 
different metabolic influences, cell cycles and states 
of cell differentiation, this projecting a high dynamical 
potential for adaptation to exogenous stress factors 
including medicaments.
Among the altered transcripts, there were mRNAs 
coding proteins responsible for the interaction 
between mRNAs and their genes-targets in different 
cells: lymphocytes, myocytes, and epithelial cells. 
This is consistent with the fact that mRNAs can act 
as paracrine and autocrine regulators of a biological 
behavior of the tumor micro-environment [14].
The changes in the mRNA profile in melanoma cells 
originated both from the center and the periphery of 
the tumor showed dysregulation of VEGFA-VEGFR2 
signaling pathway, which took part in melanoma 
pathogenesis; the up-regulation of this signaling 
pathway proteins maintained a proliferation activity 
of melanoma cells [15].
The expression of mRNAs, coding THBS1 and 
SPARC proteins, was significantly lower in cells 
obtained from the center of the tumor than in cells 
obtained from the peripheral part of the tumor. These 
genes are components of autophagy signaling pathway, 
and according to previous reports, they can take 
part in a chemoresistance formation associated with 
autophagy [16].
At the same time, for the cells obtained from the 
tumor central part, some unique signaling pathways 
were determined (Cell Cycle, Circadian rhythm 
related genes) which were not determined for the cells 
obtained from the tumor peripheral part. The change 
of an expression profile of Circadian rhythm genes 
is known to be an early occurrence in case of skin 
melanoma and is connected with the involvement of 
tumor microenvironment into this process [17].
A special role is given to melatonin that prevents 
DNA potential damage and can provide an endogenous 
enzymatic system to protect from oxidative stress 
by means of growth factor regulators and through 
activating some antioxidant enzymes, such as 
superoxide dismutase and catalase. Besides, melatonin 
in pharmacological concentrations suppresses 
proliferation of the melanoma cells [18].
For the tumor periphery cells, there were determined 
signaling cascades that were not characteristic for the 
cells from central part of the tumor: miR-targeted genes 
in leukocytes, Vitamin D Receptor Pathway, Regulation 
of Actin Cytoskeleton. Apart from calcium metabolism 
regulation, vitamin D3 active forms are also known to 
have an anticarcinogenic effect, whereas alterations 
in vitamin D signaling, including both D3 activation 
and inactivation, as well as expression and activity of 
the corresponding receptors, influence the melanoma 
progression and the outcome of the disease [19].
Conclusion
Cells obtained from the central part of the tumor 
demonstrated the increased mRNA levels of genes 
indicating a high sensitivity of cells to immunotherapy; 
in particular, these cells were characterized by enhanced 
expression of CT-antigens, as well as MAGE-A3 and 
MAGE B2 genes. These genes were considered to be 
gene-targets detected by cytotoxic T-cells in antigen-
specific immunotherapy of melanoma patients.
Melanoma cells derived from the peripheral part of 
the same tumor, had increased level of mRNA genes 
coding an extracellular matrix and inflammation-
related proteins. According to bioinformatic analysis, 
the changes in the mRNA profile in the melanoma cells 
from the tumor periphery were observed in genes-
components of the signaling pathways that took part 
in the antioxidant response. This fact suggested that 
the peripheral part of the tumor was more sensitive to 
antioxidant therapy.
Thus, the study results showed a difference between 
melanoma cells obtained from various parts of the 
primary tumor at the transcriptomic level. This fact 
should be taken into consideration when administering 
anticancer therapy.
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